Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-10-01 Director's Dealing
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-10-01 English
Director's Dealing 2021
Director's Dealing
2021-10-01 English
AMENDMENT NO. 1 TO FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports various corporate events including amendments to articles of incorporation, bylaws, and code of ethics, as well as details about a business combination transaction. The document references multiple items typical of an 8-K filing (Items 1.01, 2.01, 3.02, 4.01, 5.01, 5.02, 5.06, 7.01, 9.01, and amendments under 3.03, 5.03, 5.05). It includes no financial statements or detailed financial analysis but focuses on corporate governance changes, transaction closing, and related disclosures. Form 8-K filings are classified as Regulatory Filings (RNS) in the given taxonomy, as they are general regulatory announcements and do not constitute full financial reports or other specific report types.
2021-09-29 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It details a business combination transaction, including merger details, subscription agreements, registration rights agreements, and indemnification agreements. The document is not an annual or quarterly report, nor is it a transcript, earnings release, or proxy statement. It is a regulatory filing reporting a material event (business combination and related agreements). The length is substantial (15,000 characters), and it contains detailed event information rather than just an announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-09-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-09-28 English
Director's Dealing 2021
Director's Dealing
2021-09-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.